Welcome to our dedicated page for 908 Devices SEC filings (Ticker: MASS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
908 Devices Inc. filings document an operating company that sells common stock under MASS on the Nasdaq Global Market and reports on handheld chemical analysis tools used in health, safety and defense technology markets. Form 8-K reports furnish operating and financial results, revenue outlook materials, material-event disclosures, material agreements, capital-structure matters and related exhibits.
Proxy materials cover annual meeting voting matters, including director elections, auditor ratification, executive compensation votes and the frequency of future advisory compensation votes. The filing record also includes governance disclosures tied to board composition, annual meeting procedures, shareholder voting mechanics and emerging growth company status.
908 Devices Inc. (MASS) director Christopher D. Brown reported selling 30,000 shares of common stock on September 2, 2026, at a weighted average price of $10.58 per share in open-market or private transactions. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2025, and Brown now holds 775,559 shares directly.
908 Devices Inc. (MASS) reported that Chief Financial Officer Joseph H. Griffith IV sold 11,459 shares of common stock on August 25, 2026 in an open-market or private transaction. The weighted-average sale price was approximately $10.95 per share, with execution prices ranging from $10.65 to $11.03. Following this sale, Griffith directly holds 121,497 shares of 908 Devices Inc. common stock. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026.
908 Devices Inc. (MASS) executive Joseph Griffith, an officer of the company, filed a Rule 144 notice to sell up to 11,459 shares of common stock through Morgan Stanley Smith Barney LLC. The shares were acquired upon vesting of restricted stock units between February 1, 2025 and February 1, 2026. The filing also lists a prior 10b5-1 sale of 6,940 shares of common stock on May 28, 2026.
908 Devices Inc. (MASS) reports that AWM Investment Company, Inc., a ten percent owner, indirectly sold 50,000 shares of common stock in open-market transactions on August 20–21, 2026. The sales, executed through limited partnerships advised by AWM, occurred at weighted average prices of about $10.52–$10.61 per share.
AWM is investment adviser to several Special Situations funds and has sole voting and investment power over large share blocks they hold. AWM disclaims beneficial ownership of these shares except to the extent of its pecuniary interest.
908 Devices Inc. insider Kevin J. Knopp, President and CEO, reported selling a total of 27,622 shares of common stock in August 2026 under a Rule 10b5-1 trading plan adopted on May 20, 2025. Sales included 7,622 shares on August 13 at a weighted average $10.06 per share (actual prices ranged from $10.05 to $10.12) and 20,000 shares on August 17 at a weighted average $10.35 per share (range $10.08 to $10.45). Separately, 541,223 shares are held indirectly by The Kevin J. Knopp Irrevocable Trust of 2018, for which the trustee, Knopp’s brother-in-law, has sole voting and dispositive control; Knopp may be deemed the beneficial owner.
Kevin Knopp has filed a Form 144 indicating an intent to sell up to 20,000 shares of MASS common stock through Merrill Lynch on NASDAQ. These shares are identified as Founder Shares acquired from the issuer for cash on 02/10/2012. The filing notes that MASS had 37,813,621 common shares outstanding as of 08/17/2026 and that Knopp has sold multiple small common stock blocks in the open market over the past three months.
908 Devices Inc. received an amended Schedule 13G reporting that ARCH Venture Fund VII, L.P. is the record owner of 5,725,045 shares of Common Stock as of June 30, 2026. Through their general-partner structure, ARCH Venture Partners VII, L.P. and ARCH Venture Partners VII, LLC may be deemed to beneficially own the same shares, with shared voting and dispositive power.
Based on 41,333,705 shares of Common Stock outstanding as of August 7, 2026, each of the ARCH entities reports beneficial ownership of 13.9% of the class. Managing director Keith Crandell reports beneficial ownership of 5,824,877 shares, or 14.1%, including options and restricted stock units, and has both sole and shared voting and dispositive power over different portions of these holdings. The filing notes that each reporting person disclaims beneficial ownership except for shares held of record.
908 Devices Inc. common stock is reported as being beneficially owned by ARK Investment Management LLC and its CEO/CIO, Catherine D. Wood. They report ownership of 2,027,920 shares of common stock, representing 5.32% of the outstanding class.
ARK has sole voting and dispositive power over the 2,027,920 shares, while Catherine D. Wood reports shared voting and dispositive power over the same shares and no sole authority. The filing notes that no ARK client exceeds a 5% interest in these securities other than ARK Genomic Revolution ETF.
908 Devices Inc. received an updated ownership report from AWM Investment Company, Inc., an investment adviser to several Special Situations funds. AWM reported beneficial ownership of 4,879,773 shares of 908 Devices common stock, representing 11.8% of the outstanding class as of this filing.
AWM has sole voting and dispositive power over these shares, which are held across multiple funds: 577,077 shares by Special Situations Cayman Fund, 2,020,434 by Special Situations Fund III QP, 266,802 by Special Situations Private Equity Fund, 338,137 by Special Situations Technology Fund, and 1,677,323 by Special Situations Technology Fund II. Control of AWM and the funds’ general partners is described as resting with principals David M. Greenhouse and Adam C. Stettner.
908 Devices Inc. director Christopher D. Brown reported two open-market sales of common stock. On August 10, 2026, he sold 9,442 shares at a weighted average price of $9.03 per share, in multiple trades between $9.00 and $9.08. On August 11, 2026, he sold 8,358 shares at a weighted average price of $9.23, in trades between $9.06 and $9.36. The transactions, totaling 17,800 shares, were made pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2025.